Ionis Pharmaceuticals cut its full-year 2026 sales guidance for Tryngolza (olezarsen) to approximately 50 million dollars, from a previous range of 100 million to 110 million dollars, in its third quarter report on November 9. Tryngolza, the first approved treatment to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia, generated 9 million dollars of United States net product sales in the third quarter and 41 million dollars in the first nine months. The company said the launch is ramping more gradually than anticipated as it establishes what it calls a new treatment paradigm, and that it has identified opportunities to improve performance.
The rest of the print was stronger than the headline. Total revenue was 243 million dollars in the third quarter, up 55 percent from 157 million dollars a year earlier, and the net loss narrowed to 110 million dollars, or 0.66 dollars per share, from 129 million dollars, or 0.80 dollars per share. Dawnzera, its hereditary angioedema prophylactic, sold 37 million dollars in the quarter and remains on track for its reaffirmed full-year guidance of 110 million to 120 million dollars. Ionis reaffirmed total 2026 revenue guidance of 875 million to 900 million dollars, its operating loss guidance, and ended the quarter with 1.9 billion dollars in cash and short-term investments.
Investors focused on the cut rather than the reaffirmation. Shares fell about 27 percent on Monday, according to Seeking Alpha, a reaction that reflects what Tryngolza represents: Ionis’s first independent launch in a large indication, after decades of partnered commercialisation. The company continues to describe multi-billion-dollar peak sales potential for the drug, which is a management claim the halved first-year guide now has to be reconciled with.
Two near-term items sit behind the launch story. Tryngolza received a positive opinion from the European Committee for Medicinal Products for Human Use for severe hypertriglyceridemia, with a final European approval decision expected in the fourth quarter of 2026. And Zanvastro, the first approved disease-modifying treatment for Alexander disease and Ionis’s first independent neurology launch, has begun dosing commercial patients.